文献速递妇科肿瘤

BRCA突变铂敏感复发性卵巢癌维持奥拉帕利治疗的无进展生存列线图

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
PubMed 文献 · Eur J Cancer · 2021-07-19

该研究基于Study 19和SOLO2/ENGOT-ov21安慰剂组数据开发预测PFS的列线图,纳入CA-125、无铂间期、可测量病灶和既往铂疗线数四个预测因子。训练队列内验证C-index为0.64,验证队列(奥拉帕利)C-index为0.71,校准良好。列线图可用于预测PFS并为患者咨询和试验分层提供依据。

要点

  • 列线图纳入CA-125、无铂间期、可测量病灶和既往铂疗线数四个预测因子。
  • 训练队列中模型预测良好、中等和差风险组中位PFS分别为7.7、5.4和2.9个月。
  • 验证队列中模型预测良好、中等和差风险组中位PFS分别为未达到、16.6和8.3个月。

核心结论

  • 该列线图可预测BRCA突变铂敏感复发性卵巢癌患者维持奥拉帕利治疗的PFS,并用于患者咨询和试验分层。

研究设计与样本

  • 列线图基于Study 19和SOLO2/ENGOT-ov21安慰剂组训练队列开发,训练队列为BRCA突变高级别浆液性铂敏感复发性卵巢癌患者。
  • 采用多因素Cox回归分析基于治疗前特征开发列线图,并在接受奥拉帕利维持治疗的独立验证队列中评估区分度和验证。

主要发现

  • 训练队列(安慰剂)内验证C-index为0.64,模型预测良好、中等和差风险组中位PFS分别为7.7(95%CI 5.3-11.3)、5.4(4.8-5.8)和2.9(2.8-4.4)个月。
  • 验证队列(奥拉帕利)C-index为0.71,模型预测良好、中等和差风险组中位PFS分别为未达到、16.6(13.1-22.4)和8.3(7.1-10.8)个月。
  • 列线图在验证队列中显示良好校准(校准图)。

关键数值与推荐

  • 列线图包含四个PFS预测因子:随机化时CA-125、无铂间期、可测量病灶存在和既往铂疗线数。

临床怎么用

  • 该列线图可用于在BRCA突变铂敏感复发性卵巢癌患者开始维持奥拉帕利前预测PFS并进行咨询。
  • 该列线图可用于维持治疗试验中的患者分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer (PSROC) varies widely. Individual prognostic factors do not reliably distinguish patients who progress early from those who have durable benefit. We developed and validated a prognostic nomogram to predict PFS in these patients. METHODS: The nomogram was developed using data from a training patient cohort with BRCA mutations and high-grade serous PSROC on the placebo arm of two maintenance therapy trials, Study 19 and SOLO2/ENGOT-ov21. We performed multivariable Cox regression analysis based on pre-treatment characteristics to develop a nomogram that predicts PFS. We assessed the discrimination and validation of the nomogram in independent validation patient cohorts treated with maintenance olaparib. RESULTS: The nomogram includes four PFS predictors: CA-125 at randomisation, platinum-free interval, presence of measurable disease and number of prior lines of platinum therapy. In the training (placebo) cohort (internal validation C-index 0.64), median PFS in the model-predicted good, intermediate and poor-risk groups was: 7.7 (95% CI 5.3-11.3), 5.4 (4.8-5.8) and 2.9 (2.8-4.4) months, respectively. In the validation (olaparib) cohort (C-index 0.71), median PFS in the model-predicted good, intermediate and poor-risk groups was: not reached, 16.6 (13.1-22.4) and 8.3 (7.1-10.8) months, respectively. The nomogram showed good calibration in the validation cohort (calibration plot). CONCLUSIONS: This nomogram can be used to predict PFS and counsel patients with BRCA mutations and PSROC prior to maintenance olaparib and for stratification of patients in trials of maintenance therapies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Tjokrowidjaja A, Friedlander M, Lord SJ, et al. Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. Eur J Cancer. 2021. PMID: 34293664. doi:10.1016/j.ejca.2021.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。